Beleggers bijeenkomst Quest Photonic Devices B.V. … · 1.Identify & Demo 2. Budget allocation 3....

© 2018 Quest medical imaging B.V. Pn1

Beleggers bijeenkomst

Quest Photonic Devices B.V.

Quest medical imaging

Making the Invisible Visible

Fluorescent image guided surgery 2 © 2018 Quest medical imaging B.V. | Pn1

Disclaimer With the exception of historical information contained in this presentation, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors. The Company disclaims any obligation to update its forward-looking relationships. It is understood that here is a risk that not all current or future risks are known


Introduction

Richard Meester

• President/CEO Quest Group

• Started Company in 1998

Hendrik jan van Es

• VP Business development Quest Group

• Joined company in 2010


Introduction

Company & Structure

Key personnel

Treating cancer

Performing surgery

Battling cancer with photonics

Market (value chain)

Competitive landscape

Technology & Advantages

Strategy and business model

Milestones

Installed base

Summary

Presentation


Company Structure

Quest Innovations • Imaging Heads and Light

engines

• Production and manufacturing of Camera heads

• OEM Customers

Quest Medical Imaging • Medical end products

• Marketing & Sales

• Medical surgical application development

Quest Photonic Devices • Research and Development

of Spectral Imaging Systems


Main Personnel Richard Meester

• President/CEO Quest Group

• Started Company in 1998

• 20+ years experience in Imaging Systems and business management

Hendrik jan van Es • VP Business development Quest Medical Imaging B.V. (Benelux)


• 15+ years in business development and market strategy

Rob NGungu • COO Quest Medical Imaging Inc. (USA)


• 25+ years experience in regulatory filings with FDA

Frederic Wasielewski • Sales Director Quest Medical Imaging SAS (France)

• 15+ years in medical device sales



Milestones


Cancer


Cancer Key is

removing the complete tumor during surgery

Any residual cancer cells increase chance of recurrance


Treating cancer

Lifestyle Detection Biopsy/

Analysis Localize Therapy Result

Monitor &

Recurrence

Quest Medical

Product Focus Quest Innovations

customers


Company position in the chain


Everybody is different

Treatment

Treatment


Improve surgical performance

Improve treatment process

• Localize (CT/MRI)

• Treatment (Surgical)

• Result (Pathology & Follow up)

Provide real time tissue

information to surgeon

Improve patient care overall

Focus on surgical intervention

Localize Therapy Result


How to:

Identify the Tumor during surgery • CT/MRI done before, no real time imaging

Identify complete tumor removal

Identify remaining small tumor spread • CT/MRI resolution may not detect small tumors

Person is located differently, organs have shifted

Detection of vital structures

Detection of tissue types

Navigation through human body (specifically minimal invasive)

Patient information, everybody is different

Surgical Challenges


You can visualize information to the surgeon in real

time instead of simulation?

What if:


Targeted tumor examples

Color NIR Fluorescence

Color - NIR Merge

Cases at Leiden University Medical Center. A. Vahrmeyer. Targeted tumor agent ovarian


Targeted lymph node examples

Cases at Leiden University Medical Center. A. Vahrmeyer. Targeted tumor agent in lymph node


Clasification • Ex vivo study

- Pathology

- Spectral imaging

- False color indication of spectral similarities

• Tumor detection

• Currently only superficial

• Aid for different applications like: - Cervical cancers

- Melanoma tumor bed scan

Use other body chromophores than just blood

Requires OR environment control

Tissue tumor detection &

segmentation

Healthy tissue Tissue with tumor

Dept. of Surgery, Leiden University Medical Center, The Netherlands


LUMC Presentation on moleculair imaging

Battling cancer with Photonics


Company

Technology

Strategic partners

Market development

Socially

Improving patient outcome

Lowering costs for hospital and society

Why invest in Quest? Prism Technology

The camera is actually several cameras behind one lens, making perfect overlays possible


Competition

Storz Mini Flare Fluobeam PDE Hypereye Pinpoint/Spy

Strong Add-on on tower Well developed distribution

Large install base Large install base (Mostly Japan)

Computer overlaid image

Large install base (Luna via Life Cell)

Relative Low price

Computer overlaid image Low price Low price

More market ready company + system

Weak Switching image Only NIR vision Only NIR vision No data collection Single Chip solution

Bad NIR image

Cannot be CE/ FDA certified

ICG or Methylene blue Can do only ICG Can do only ICG Can do only ICG

Only open system Only open system Only open system Only open or MIS system

Technical inferior Technical inferior Technical inferior Technical inferior Technical inferior


Smart tumor targeting contrast agent provides

• 4 contracted 4 in progress

One agent works only with our camera

Registering exclusively with us (FDA)

Capability of seeing more than one agent at the time

Partnerships contrast agents


Installed base


Currently at the following locations

• #2 Memorial Sloan Kettering Cancer Center, new York

• #7 Cleveland Clinic, Cleveland

• #7 Upenn, Philadelphia

• #10 UCSF, San Diego

Goal focus on installing units at complete top 10.

Top 10 Cancer centers US


Partners


Camera systems

Novadaq => Stryker $ 701 Mln

Surgvision => Bracco $?

Vision sense => Medtronic $ 75 Mln

Targeted probes

On Target => Johnson & Johnson $ 40 Mln

Partners => Total investment last 3 yrs (> 150 Mln)

Recent take overs / investments


Milestones

- 2017 ICG open application phase 2018 - 2019

ICG open & MIS applications phase 2020

Expected Start Targeted probe roll out phase. Gen 3 system

Key priority: - Build out distributor

network and via them install systems in key hospitals, building out install base.

- Build out production hospitals (not only university hospitals

- Expand product line

2021 Adding modules / integrate with OR setup

Several additional modalities are under development that can be added to the towers in the field.

The first targeted probes will have completed registration. Joint roll out based on install base already in place, distributor network of QMI and sales structure of probe developer.

Key priorities: - Recruitment of Sales

manager France/ internal sales/ clinical assistant

- Formalize agreements with 3 Probe developers


Sales cycle

1.Identify & Demo

2. Budget allocation

3. Rent/

Sale

Step sales approach

1. Predefined target hospital list

Demonstrate machine in real use (perform surgery with surgeon)

2. Find budget

3. Acquire machine or place through rental or pay per surgery

Average sales cycle 9 – 15 months

Rental with option to buy shortens cycle

Pay per surgery easiest. Pay through kit (US only right now)


Increase distribution network • New distributors under negotiation to close this year

• Increase demo systems

• Increase device production

Increase direct sales network • US East coast (Sales reps + clinical assistants)

• US West coast (Sales reps + clinical assistants)

• US Central clinical assistants

• Germany office (Sales reps + clinical assistants)

Strengthen office backbone

Build out product portfolio and technology

Short term action points


Questions

Pn1 © 2018 Quest medical imaging B.V.

Quest Medical Imaging B.V.

PO Box 22, 1770 AA, Wieringerwerf

the Netherlands

T:+31(0)227 604046 ◊ F:+31(0)227 604053

www.quest-innovations.com/ www.quest-mi.com

http://www.quest-innovations.com/



http://www.artemismi.com/



Date post:	13-Sep-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Beleggers bijeenkomst Quest Photonic Devices B.V. … · 1.Identify & Demo 2. Budget allocation 3....

Documents